Simply Wall St has raised its internal fair value reference for P3 Health Partners to $14.00 from $10.25, following the company's first-quarter 2026 adjusted EBITDA of $26 million and an increased full-year EBITDA guidance midpoint of about $30 million. TD Cowen lifted its price target to $14 from $3, while Lake Street raised its target to $14 from $4, citing a shored-up balance sheet after debt was converted to equity. Lake Street cautioned that it may take a couple more quarters for sentiment to fully shift, which could limit near-term valuation re-rating. The fair value update also reflects revised assumptions, including a revenue growth rate lowered to 6.19% from 11.10% and a net profit margin raised to 6.10% from 5.17%.
P3 Health Partners IncFair value reference raised to $14, price targets lifted by analysts, and strong EBITDA and guidance reported.